Legal & General Group Plc Invests $8.74 Million in Bruker Corporation $BRKR

Legal & General Group Plc purchased a new position in Bruker Corporation (NASDAQ:BRKR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 145,259 shares of the medical research company’s stock, valued at approximately $8,742,000. Legal & General Group Plc owned 0.10% of Bruker as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Los Angeles Capital Management LLC acquired a new stake in Bruker during the fourth quarter worth about $26,000. Global Retirement Partners LLC acquired a new position in shares of Bruker in the 2nd quarter valued at approximately $38,000. Parallel Advisors LLC lifted its holdings in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the period. Allworth Financial LP boosted its position in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares in the last quarter. Finally, Essential Partners LLC acquired a new stake in shares of Bruker during the 1st quarter worth approximately $36,000. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $56.03 on Wednesday. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The company has a market cap of $8.54 billion, a price-to-earnings ratio of -80.04, a PEG ratio of 1.77 and a beta of 1.26. The firm has a 50 day simple moving average of $58.82 and a 200 day simple moving average of $48.26.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts predict that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be given a dividend of $0.05 per share. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is currently -28.57%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Barclays lifted their price target on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. UBS Group set a $60.00 price target on Bruker in a report on Wednesday, June 24th. Citigroup dropped their price objective on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. Finally, Wolfe Research started coverage on Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.